In BRAF‐mutant melanoma, ZEB1 is sufficient and only partly compensated by TWIST to promote an undifferentiated p75high neural crest stem cell‐like state that is characterized by resistance to MAPK and BRAF inhibitors (Richard et al, 2016; Shaffer et al, 2017; Rambow et al, 2018). Here, BRAF is linked to melanoma.